Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 6 Systemic infusion of BQ-788 (300 nmol/min), a selective ETB-receptor antagonist, in healthy subjects increases systemic vascular resistance (SVR) and decreases heart rate (HR), cardiac index (CI) and stroke volume index (SVI). There was no significant change in systemic arterial blood pressure (MAP). (Modified from [206]).
|
